Athersys, Inc. (NASDAQ:ATHX) received a $12.00 price objective from investment analysts at Maxim Group in a report issued on Thursday, October 5th. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective points to a potential upside of 453.00% from the company’s previous close.
The analysts wrote, “A negative blogger blasted Athersys Multistem with Zombie” like properties as a therapeutic that just won’t die. The article (in our opinion) picks and chooses elements of the Athersys story which when taken out of context paint a confusing picture.””
Several other research firms have also recently issued reports on ATHX. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a report on Monday, August 14th. ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Athersys presently has a consensus rating of “Hold” and a consensus target price of $7.17.
Shares of Athersys (NASDAQ ATHX) traded down 3.56% during midday trading on Thursday, reaching $2.17. The company’s stock had a trading volume of 1,159,447 shares. Athersys has a 1-year low of $1.02 and a 1-year high of $2.63. The stock has a 50 day moving average of $2.17 and a 200-day moving average of $1.69. The company’s market capitalization is $247.19 million.
Athersys (NASDAQ:ATHX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.96 million. During the same quarter in the prior year, the firm earned ($0.08) EPS. Athersys’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities research analysts anticipate that Athersys will post ($0.24) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Athersys, Inc. (NASDAQ:ATHX) PT Set at $12.00 by Maxim Group” was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/athersys-inc-athx-given-a-12-00-price-target-by-maxim-group-analysts/1692818.html.
In other news, insider William Lehmann, Jr. sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $2.38, for a total value of $35,700.00. Following the completion of the transaction, the insider now directly owns 527,380 shares in the company, valued at $1,255,164.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 9.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Athersys by 19.5% in the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after acquiring an additional 637,322 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Athersys by 4.8% during the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 2,800 shares in the last quarter. Teachers Advisors LLC boosted its holdings in Athersys by 21.9% during the fourth quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 28,178 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Athersys by 35.2% during the first quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock worth $1,292,000 after buying an additional 196,981 shares in the last quarter. Finally, FNY Partners Fund LP bought a new stake in Athersys during the first quarter worth approximately $206,000. Institutional investors and hedge funds own 19.08% of the company’s stock.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with our FREE daily email newsletter.